- Home
- EDF vs MSLE Comparison
EDF vs MSLE Comparison
Compare EDF & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EDF | MSLE |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.0M | 186.9M |
| IPO Year | 2010 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EDF | MSLE |
|---|---|---|
| Price | $4.29 | $6.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.17 |
| AVG Volume (30 Days) | ★ 160.7K | 64.2K |
| Earning Date | 01-01-0001 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $5.44 |
| 52 Week High | $5.67 | $13.39 |
Technical Indicators
Market Signals| Indicator | EDF | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 27.87 | 32.08 |
| Support Level | N/A | $5.52 |
| Resistance Level | $5.41 | $10.58 |
| Average True Range (ATR) | 0.13 | 0.58 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 2.78 | 7.39 |
Price Performance
Historical ComparisonAbout EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.